Welcome to our dedicated page for DAMORA THERAPEUT news (Ticker: DMRA), a resource for investors and traders seeking the latest updates and insights on DAMORA THERAPEUT stock.
Damora Therapeutics, Inc. reports news around its biotechnology pipeline for mutCALR-driven blood disorders, financial results, and corporate development following the completed acquisition that added DMR-001, DMR-002, and DMR-003. Company updates also describe governance changes, board and executive appointments, and equity compensation actions under Nasdaq inducement-grant rules.
Recurring Damora news centers on hematologic disorders, myeloproliferative neoplasms, research and development progress, capital resources, and public-company governance matters tied to its Nasdaq-listed common stock.
Damora Therapeutics (NASDAQ: DMRA) reported first quarter 2026 results and pipeline progress. Cash and equivalents were $532.9 million as of March 31, 2026, expected to fund operations into 2029. Net loss was $27.8 million, with higher R&D and G&A expenses as programs advance.
Damora plans first regulatory submissions for DMR-001 in mid-2026, DMR-002 in second-half 2026, and DMR-003 in 2027, with two DMR-001 proof-of-concept datasets anticipated beginning mid-2027. DMR-001 preclinical data will be presented at the 2026 European Hematology Association Congress. The company also appointed Jennifer Jarrett as CEO and expanded its leadership team and board.
Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to two newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). The awards are non-qualified stock options for an aggregate of 57,500 shares, 10-year term, exercise price $25.66 per share.
Options vest 25% after one year then monthly over 36 months and are governed by the 2022 Inducement Plan and individual option agreements.
Damora Therapeutics (NASDAQ: DMRA) announced inducement equity grants tied to recent hires and its new President and CEO, Jennifer Jarrett, on March 24 and March 30, 2026. The company granted non-qualified options totaling 74,000 shares to four non-executive hires at $23.05, with a 10-year term.
Ms. Jarrett received 500,000 RSUs and non-qualified options to purchase 1,500,000 shares at an exercise price of $25.50. Options vest 25% after one year, then monthly over 36 months; RSUs vest annually over four years. Grants were approved under Nasdaq Listing Rule 5635(c)(4) and subject to Damora's 2022 Inducement Plan and award agreements.
Damora Therapeutics (NASDAQ: DMRA) appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and added biotech leaders Cameron Turtle and Mike Landsittel to the Board. Peter Harwin was named Chairman. Management changes accompany a focus on advancing lead program DMR-001 and portfolio development.
Damora Therapeutics (NASDAQ: DMRA) reported full-year 2025 results and corporate milestones on March 19, 2026. The company completed acquisition of mutCALR-focused assets, raised gross proceeds of approximately $285 million (private) and $316 million (public), and holds about $535 million in cash as of February 28, 2026. Damora expects an IND/CTA for lead candidate DMR-001 by mid-2026 and two proof-of-concept datasets beginning mid-2027.
2025 results include R&D expense of $26.9M, G&A of $9.7M, and a net loss of $209.8M largely driven by a $174.3M acquired in-process R&D charge.